Table 2 Comparative characteristics of patients with BRCA1-mutated HGSOC receiving NACT combination of mitomycin C, doxorubicin and cisplatin versus women treated by paclitaxel plus carboplatin
Clinical characteristics | MAP group (N = 10) | TCbP group (N = 16) | Statistical comparison |
|---|---|---|---|
Median age of onset (range) | 50 (35–64) | 49 (37–72) | Not significant |
Pattern of BRCA1 mutations | c.5266dupC (n = 5), c.4034delA (n = 3), c.68_69delAG (n = 1), c.1961delA (n = 1) | c.5266dupC (n = 2), c.4034delA (n = 2), c.68_69delAG (n = 1), C61G (n = 1), c.1510delC (n = 1), Q563X (n = 1), c.2076dupT (n = 1), c.2983_2984delAA (n = 1), c.3247del5 (n = 1), c.3601_3602delGG (n = 1), c.3718_3719delCA (n = 1), Y1509X (n = 1), G1706E (n = 1), c.5152 + 1G > T (n = 1) | p = 0.005 (founder vs. non-founder mutations; Fisher’s exact test) |
FIGO stage | |||
IIIC | 5 (50 %) | 12 (75 %) | p = 0.23 (stage III vs. IV; Fisher’s exact test) |
IVA | 1 (10 %) | 2 (13 %) | |
IVB | 4 (40 %) | 2 (13 %) | |
NACT cycles (range) | 3–5 | 3–8 | |
Cytoreduction | |||
Optimal | 9 (90 %) | 14 (88 %) | p = 1.0 (Fisher’s exact test) |
Suboptimal | 1 (10 %) | 1 (6 %) | |
None | 0 | 1 (6 %) | |
Response by RECIST | |||
CR | 0 | 0 | p = 0.12 (objective response vs. lack of objective response; Fisher’s exact test) |
PR | 10 (100 %) | 11 (69 %) | |
SD | 0 | 4 (25 %) | |
PD | 0 | 1 (6 %) | |
Chemotherapy response score (CRS) in the ovaries | |||
CRS 1 | 0 | 6 (38 %) | p = 0.05 (CRS 1 vs. other; Fisher’s exact test) |
CRS 2 | 8 (80 %) | 9 (56 %) | |
CRS 3 | 1 (10 %) | 0 | |
Tissue not available for evaluation | 1 (10 %) | 1 (10 %) | |
Chemotherapy response score (CRS) in the omentum | |||
CRS 1 | 0 | 5 (31 %) | p = 0.12 (CRS 1 vs. other; Fisher’s exact test) |
CRS 2 | 5 (40 %) | 8 (50 %) | |
CRS 3 | 1 (10 %) | 0 | |
No tumor cells | 4 (40 %) | 2 (13 %) | |
Tissue not available for evaluation | 0 | 1 (6 %) | |
ACT cycles (range) | 1–6 | 1–6 | |
Median follow-up, months (range) | 30.1 (15.8–36.6) | 23.4 (10.7–45.2) | p = 0.28 (Mann-Whitney Test) |
Median treatment-free interval (95 % CI) | Not reached | 9.5 (7.8–11.2) | p = 0.109 (Log Rank [Mantel-Cox]) |
Recurrence within one year after completion of treatment | 4 (40 %) | 10/13a (77 %) | p = 0.1 (Fisher’s exact test) |